Method for determining facial muscle responses
A method for quantitatively assessing muscle contraction and corresponding kits are described. The method can include assessing muscle contraction of a facial muscle by applying an external electrical stimulus to facial skin sufficient to contract a facial muscle, and measuring the contractile activity of the contracted facial muscle. The method can be used to determine the ability of a treatment material to reduce contraction of the facial muscle.
1 . A method for quantitatively assessing muscle contraction of a facial muscle in a person and determining the ability of a treatment material to reduce contraction of the facial muscle, the method comprising:
(a) applying an external electrical stimulus of 2 mV to 10 mV of electricity at 2 to 4 second intervals for 5 to 15 intervals to facial skin sufficient to contract a facial muscle; and
(b) measuring the contractile activity of the contracted facial muscle by measuring the compound motor action potential (CMAP) of the contracted facial muscle to obtain a first average measurement of contractile activity of the contracted facial muscle; and then
(c) administering the treatment material by topically applying the treatment material to the facial skin; and
(d) repeating steps (a) and (b) to obtain a second average measurement of contractile activity of the contracted facial muscle,
wherein a decrease in contractile activity based on the second average measurement as compared to the first average measurement indicates that the treatment material reduces contraction of the facial muscle when administered to the facial skin, and
wherein the method for quantitatively assessing muscle contraction of the facial muscle does not rely on the use of voluntary contractions of the facial muscle by the person.
2 . The method of claim 1 , wherein the treatment material comprises a chemical compound, a protein, a peptide, a botanical plant/plant part, or a bacteria, or combinations thereof.
3 . The method of claim 2 , wherein the treatment material is a protein.
4 . The method of claim 2 , wherein the protein is Clostridium botulinum toxin.
5 . The method of claim 1 , wherein the treatment material is comprised in a topical skin formulation selected from an emulsion, a gel, an ointment, or a solution.
6 . The method of claim 5 , wherein the topical skin formulation is an oil-in-water emulsion.
7 . The method of claim 1 , further comprising obtaining a first image of the facial skin prior to administering the treatment material and obtaining a second image of the skin after administering the treatment material.
8 . The method of claim 7 , wherein the first and second images are used to determine the effectiveness of the treatment material to reduce the appearance of rhytides present on the facial skin.
9 . The method of claim 1 , wherein measuring the contractile activity of the contracted facial muscle further comprises measuring the electrical activity of the contracted facial muscle.
10 . The method of claim 1 , wherein measuring the contractile activity of the contracted facial muscle further comprises surface electromyography.
11 . The method of claim 1 , wherein the external electrical stimulus is generated from a conductive material having a square shape, a rectangular shape, a circular shape, or a triangular shape.
12 . The method of claim 1 , wherein the facial muscle is a glabellar complex muscle, an orbicularis oculi muscle, a depressor muscle, or a frontalis muscle, or any combination thereof.
13 . The method of claim 1 , wherein the facial skin includes a rhytide.